Antitumour activity of Oncamex demonstrated in pre-clinical breast cancer models

Released: Friday 1st April 2016

OncamexTM is a proprietary, synthetic flavonoid derivative being developed by Antoxis for use as an anticancer agent. The compound, which is rapidly absorbed into tumour cells, has been shown to target the cell mitochondria where it modulates the redox environment. Studies have now been completed in pre-clinical breast cancer models, which demonstrate the antitumour activity of this novel-acting agent. Further details can be found by following this link


View all News